Recombinant beta-serine-interferon in hairy cell leukemia compared prospectively with results with recombinant alpha-interferon.
Ten patients with hairy cell leukemia (HCL) requiring therapy were treated with recombinant beta-serine-interferon (rIFN-beta ser) (90 x 10(6) units [U] subcutaneously three times a week). Eight patients were evaluable for response and nine for toxicity. Five patients (63%) showed normalization of peripheral blood counts, and an additional two patients (25%) showed improvement in at least one hematologic variable. Persistent hairy cells were detected in the bone marrow of all patients at the completion of therapy. All patients experienced influenza-like symptoms which were not dose limiting and which resolved with continued therapy. Erythema and induration at interferon injection sites developed in five patients (56%); one required dose reduction and another was removed from the study for this reason. Data from matched historical controls treated with recombinant alpha-interferon are presented for comparison. We conclude that rIFN-beta ser has activity in HCL.
Glaspy
J A
JA
Department of Medicine, UCLA School of Medicine 90024-1678.
Marcus
S G
SG
Ambersley
J
J
Golde
D W
DW
D005260:Female; D006801:Humans; D007370:Interferon Type I / Q000009:adverse effects / Q000627:therapeutic use*; D000068556:Interferon beta-1a; D000068576:Interferon beta-1b; D016899:Interferon-beta; D007943:Leukemia, Hairy Cell / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use
D007370:Interferon Type I; D011994:Recombinant Proteins; D000068576:Interferon beta-1b; D016899:Interferon-beta; D000068556:Interferon beta-1a